Join our daily newsletter At The Bell to receive exclusive market insights
- Telix Pharmaceuticals (TLX) has been granted authorisation for Illuccix, the company’s lead prostate cancer imaging product
- Illuccix, a PET imaging agent, targets a prostate specific membrane antigen which appears on more than 90 per cent of primary and metastatic prostate cancer cells
- The granted use comes from Brazilian health regulatory agency, Anvisa and will allow Telix to start sales as early as next year
- The authorisation has been passed on to Telix’s partner, Grupo RPH, Brazil’s leading cold kit plant and radiopharmacy network
- Company shares are in the red by 2.88 per cent at $6.41
Telix Pharmaceuticals (TLX) has been granted authorisation for Illuccix, the company’s lead prostate cancer imaging product.
Illuccix is a PET imaging agent which targets a prostate specific membrane antigen, a protein which is overexpressed on the surface of more than 90 per cent of primary and metastatic prostate cancer cells.
The granted use comes from Brazilian health regulatory agency, Anvisa, and will allow Telix to start sales as early as next year.
The authorisation has been passed on to Telix’s partner, Grupo RPH, Brazil’s leading cold kit plant and radio pharmacy network.
The Anvisa approval highlights wide-spread clinical access to modern prostate cancer imaging for all men across Brazil.
Telix CEO and managing director, Dr Christian Behrenbruch, says prostate cancer has a huge impact across Brazil.
“Prostate cancer is the most commonly diagnosed male cancer in Brazil, with approximately 65,840 new cases each year. PSMA-PET imaging has the potential to have a profound impact on the management of prostate cancer, enabling clinicians to detect prostate cancer right throughout the body,” he said.
Grupo RPH Nuclear Medicine and Innovation Vice-President, Rafael Madke, also commented.
“We are very pleased to have received this exceptional authorisation for Illuccix in Brazil, which is only given in select circumstances, and we look forward to playing an important role in transforming outcomes for men with prostate cancer.”
Telix Pharmaceuticals shares are 2.88 per cent in the red at $6.41 at 2:50 pm AEDT.
